Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)

Abstract

BackgroundThis was a prospective phase II study of cisplatin and bortezomib (CB) in the first line treatment of malignant pleural mesothelioma (MPM) with validation of progression free survival rate at 18weeks (PFSR-18)1 as primary end-point. MethodsChemotherapy-naïve patients with histologically proven MPM and performance status (PS) 0/1, were treated with cisplatin 75mg/m2 on day 1 and bortezomib 1.3mg/m2 on days 1, 4, 8, 11 every 3weeks. The primary end-point validation utilised the landmark method. ResultsBetween 2007 and 2010 82 patients were entered. PFSR-18 was 53% (80% confidence intervals, CIs, 42–64%). The overall survival (OS) was 13.5months (95% CI 10.5–15) with 56% (95% CI 44–66%) alive at 1year. The median PFS was 5.1months (95% CI 3.3–6.5) and the response rate was 28.4% (95% CI 18.9–39.5%).The most frequent grade 3–4 toxicities were hyponatremia (46%), hypokalaemia (17%), fatigue (12.2%), thrombocytopenia (11%), neutropenia (9.7%) and neurotoxicity (motor, sensory, other: 1.2%, 8.5%, 2.4%). There were two toxic deaths (32 and 74days) due to acute pneumonitis and cardiac arrest.End-point validation showed that patients with no progression/progression at 18weeks had median OS of 16.9/11.9months, respectively. Hazard ratio was 0.46 (CI 0.32–0.67), logrank test and C-index were 0.007 and 0.60. ConclusionThe 50% PFSR-18 for CB was contained within the 80% CI for (42–64%). Therefore the null hypothesis could not be rejected. Accordingly this combination does not warrant further investigation. PFSR-18 was confirmed as a strong predictor of survival.